{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:57:03Z","timestamp":1790611023060,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T00:00:00Z","timestamp":1160352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Authors from the UK present a systematic review of publications on the safety and efficacy of anticholinergics in men with LUTS; they found them to be safe, but suggested that further studies are required to establish precisely their efficacy.<\/jats:p>\n                    <jats:p>Authors from the USA studied the correlation between risk factors for vascular disease and the AUA symptom score; there was a possible association between vascular disease and the development and severity of LUTS in men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of anticholinergics in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) by a systematic review of published reports and a meta\u2010analysis of the reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      We searched Medline, Embase and Cochrane databases (1966\u20132006), and hand\u2010searched relevant reference lists and conference proceedings, for studies on the use of anticholinergics in men with BPH or bladder outlet obstruction. Eligible studies were assessed for quality and foreign language studies were translated. We collected data on all reported outcomes, conducted meta\u2010 analyses on the maximum urinary flow rate (Q\n                      <jats:sub>max<\/jats:sub>\n                      ), postvoid residual urine volume (PVR) and volume at first contraction, and calculated the acute urinary retention (AUR) rate. We used sensitivity analysis to confirm the findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      We identified five randomized controlled trials (RCTs) and 15 observational studies. Four RCTs incorporating 633 patients were included in the meta\u2010analyses. Anticholinergics did not significantly alter Q\n                      <jats:sub>max<\/jats:sub>\n                      (0.1\u2003mL\/s, 95% confidence interval, CI, 0.6\u20130.7). The PVR was increased by 11.6\u2003mL (95% CI 4.5\u201318.6) although there was no significant difference between AUR rates. The total International Prostate Symptom Scores (IPSS) were not significantly different, but there were improvements for IPSS storage subscores in one RCT. The AUR rate was 0.3% at the 12\u2010week follow\u2010up in 365 men in the RCTs and observational studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Anticholinergic use in men with LUTS suggestive of BPH appears to be safe. Further studies are required to establish efficacy with a suitable precision.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06574.x","type":"journal-article","created":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T04:31:53Z","timestamp":1160368313000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"99","author":[{"given":"Benedict T.","family":"Blake\u2010James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rashidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,7]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.08.015"},{"key":"e_1_2_8_3_2","first-page":"203","volume-title":"Incontinence, 2nd International Consultation on Incontinence","author":"Koelbl H","year":"2002"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.09.050"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35874-3"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000049775"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1980.tb03107.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.02.024"},{"key":"e_1_2_8_11_2","first-page":"CD003781","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","volume":"3","author":"Hay\u2010Smith J","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee.","year":"2003","journal-title":"J Urol"},{"key":"e_1_2_8_13_2","volume-title":"British National Formulary 51.","author":"Anonymous.","year":"2006"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.150"},{"key":"e_1_2_8_15_2","volume-title":"Undertaking Systematic Reviews of Research on Effectiveness","author":"Khan KS","year":"2001"},{"key":"e_1_2_8_16_2","first-page":"128","article-title":"A controlled, double\u2010blind, cross\u2010over study of terodiline in motor urge incontinence","volume":"76","author":"Lukkarinen O","year":"1987","journal-title":"Ann Chir Gynaecol"},{"key":"e_1_2_8_17_2","first-page":"724","article-title":"[Clinical evaluation of long\u2010term administration of terodiline hydrochloride for the treatment of patients with pollakisuria and incontinence]","volume":"34","author":"Tsujimoto Y","year":"1988","journal-title":"Hinyokika Kiyo"},{"key":"e_1_2_8_18_2","first-page":"187","article-title":"Relation of the antispasmodic anisotropine methylbromide to parasympathetic control of the male urinary tract","volume":"8","author":"Voss HE","year":"1966","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_2_8_19_2","first-page":"733","article-title":"[Clinical effects of terodiline hydrochloride for urinary frequency and sense of residual urine]","volume":"34","author":"Fujiwara E","year":"1988","journal-title":"Hinyokika Kiyo"},{"key":"e_1_2_8_20_2","unstructured":"LeeKS KimDY KimJCet al.Combination treatment with propiverine hydrochloride plus doxazosin GITS in men with overactive bladder coexisting benign prostatic obstruction: a prospective randomized controlled multicenter study.Proceedings of the International Continence Society 2004: 34th Annual Meeting with the International UroGynecological Association Paris France2004:Abstract207"},{"key":"e_1_2_8_21_2","doi-asserted-by":"crossref","first-page":"Abstract","DOI":"10.1016\/S0022-5347(18)38166-7","article-title":"Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers (Abstract AUA Annual Meeting)","volume":"171","author":"Kaplan SA","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_8_22_2","first-page":"477","article-title":"Identifying patients with benign prostatic hyperplasia with overactive bladder and determining the efficacy of combination therapy with alpha blocker and tolterodine","volume":"169","author":"Lee JY","year":"2003","journal-title":"J Urol"},{"key":"e_1_2_8_23_2","unstructured":"OkadaH ShirakawaT SengokuAet al.Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia.Proceedings of the International Continence Society 2003: 33rd Annual Meeting Florence Italy.Abstract508"},{"issue":"2","key":"e_1_2_8_24_2","first-page":"29","article-title":"Safety and tolerability of tolterodine in men with bladder outlet obstruction and symptomatic detrusor overactivity","volume":"15","author":"Abrams P","year":"2005","journal-title":"Progr\u00e8s En Urologie"},{"key":"e_1_2_8_25_2","first-page":"1048","article-title":"Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns","volume":"167","author":"Abrams P","year":"2002","journal-title":"J Urol"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(02)80513-9"},{"key":"e_1_2_8_27_2","first-page":"547","article-title":"Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO)","volume":"20","author":"Abrams P","year":"2001","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_8_28_2","first-page":"308","article-title":"Combination treatment with an \u03b1\u2010blocker plus an anticholinergic improves quality of life in patients with bladder outlet obstruction. A prospective, randomized, controlled study","volume":"21","author":"Athanasopoulos A","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00483-0"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173630.94559.fd"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000067541.73285.eb"},{"key":"e_1_2_8_32_2","first-page":"525","article-title":"A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and\/or urinary incontinence","volume":"12","author":"Saitoh H","year":"1999","journal-title":"Jap J Urol Surg"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000282787"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000181823.33224.a0"},{"issue":"2","key":"e_1_2_8_35_2","first-page":"25","article-title":"Initial \u03b1\u2010blocker and anticholinergic combined treatment in overactive bladder\/benign prostatic obstruction (OAB\/BPO) patients","volume":"15","author":"Lee JY","year":"2005","journal-title":"Progr\u00e8s En Urologie"},{"key":"e_1_2_8_36_2","unstructured":"LimE ChiaSJ.Combination therapy using alpha\u2010blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious?.Proceedings of the International Continence Society 2005: 35th Annual Meeting Montr\u00e9al Canada.Abstract205"},{"key":"e_1_2_8_37_2","first-page":"670","article-title":"[Pharmacological evaluation of efficacy and safety of propiverine hydrochloride in patients of overactive bladder: Relationship between urodynamic observation and propiverine pharmacokinetics]","volume":"96","author":"Sugiyama T","year":"2005","journal-title":"Nippon Hinyokika Gakkai Zasshi"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05039.x"},{"key":"e_1_2_8_39_2","first-page":"191","article-title":"The treatment of overactive bladder symptoms related to benign prostatic hyperplasia with an anticholinergic agent","volume":"15","author":"Sugiyama T","year":"2004","journal-title":"NBS (J Jap Neurogenic Bladder Society)"},{"key":"e_1_2_8_40_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-5347(18)38583-5","article-title":"Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia","volume":"171","author":"Okada H","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_8_41_2","unstructured":"SuzukiY TakasakaS KishimotoKet al.Combination treatment with an alpha1\u2010blocker plus an anticholinergic for the patients with suspected bladder outlet obstruction (BOO) concomitant with over\u2010active bladder (OAB). (Abstract).Proceedings of the International Continence Society 2004; 34th Annual Meeting with the International UroGynecological Association Paris France:Abstract471"},{"key":"e_1_2_8_42_2","unstructured":"CucciA ColliE.Bladder voiding dynamics in BPH patients treated with high dose flavoxate.Proceedings of the International Continence Society 1990; 20th Annual Meeting Aarhus Denmark.Abstract119: 215\u20136"},{"key":"e_1_2_8_43_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/030006058701500507","article-title":"Treatment of urgency and urge incontinence with flavoxate in the People\u2019s Republic of China","volume":"15","author":"Gu FL","year":"1987","journal-title":"J Int Med Res"},{"key":"e_1_2_8_44_2","first-page":"1974","article-title":"A clinical study of bladderon in BPH patients","volume":"19","author":"Fujinaga T","year":"1982","journal-title":"Med Consultation New Remedies"},{"key":"e_1_2_8_45_2","first-page":"1478","article-title":"A clinical study of Bladderon tablets in patients with benign prostatic hypertrophy","volume":"30","author":"Rokiyo M","year":"1981","journal-title":"Shinyaku Rinsho"},{"key":"e_1_2_8_46_2","first-page":"1055","article-title":"A multicenter clinical trial of flavoxate hydrochloride","volume":"43","author":"Niijima M","year":"1981","journal-title":"Nishinihon J Urol"},{"key":"e_1_2_8_47_2","first-page":"1617","article-title":"Clinical effects of Bladderon tablets against nocturnal pollakiuria in BPH patients","volume":"30","author":"Yoshida H","year":"1981","journal-title":"Shinyaku Rinsho"},{"key":"e_1_2_8_48_2","first-page":"1481","article-title":"A clinical study of combined therapy with Eviprostat and Bladderon tablets in BPH patients","volume":"30","author":"Ikegami S","year":"1981","journal-title":"Shinyaku Rinsho"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042307-200401000-00003"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-003-0022-2"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000176460.62847.23"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta7410"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00067-4"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706629"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06574.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06574.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:57:38Z","timestamp":1761757058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06574.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,7]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06574.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06574.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,7]]},"assertion":[{"value":"2006-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}